Synthesis of Bis(7-Methyl-2- or 6-Purinyl) Disulfides
作者:Alicja Kowalska
DOI:10.1080/10426500701542734
日期:2007.10.18
Substituted 7-methyl-2- or 6-purinethiones were obtained in series of reactions by nucleophilic substitution with oxygen, chloro, and sulfur nucleophiles. Oxidation of the sulfur atom at position 6 or 2 in purinethiones to corresponding disulfides depended on the conditions of the reaction and oxidizing agent.
Czauderna, Marian; Samochocka, Krystyna, Journal of the Chemical Society. Perkin transactions II, 1983, p. 765 - 768
作者:Czauderna, Marian、Samochocka, Krystyna
DOI:——
日期:——
PEGylated mesoporous silica as a redox-responsive drug delivery system for loading thiol-containing drugs
作者:Qinfu Zhao、Chen Wang、Ying Liu、Jiahong Wang、Yikun Gao、Xiaojing Zhang、Tongying Jiang、Siling Wang
DOI:10.1016/j.ijpharm.2014.10.056
日期:2014.12
In this paper, we describe the development of a redox-responsive delivery system based on 6-mercaptopurine (6-MP)-conjugated colloidal mesoporous silica (CMS) via disulfide bonds. mPEG was modified on the surface of silica to improve the dispersibility and biocompatiblity of CMS by reducing hemolysis and protein adsorption. The CMS carriers with different amounts of thiol groups were prepared to evaluate the impact of modified thiol on the drug loading efficiency. In vitro release studies demonstrated that the CMS nanoparticles exhibited highly redox-responsive drug release. The cumulative release of 6-MP was less than 3% in absence of GSH, and reached more than 70% within 2 h in the presence of 3 mM GSH. In addition, by comparing the cumulative release profiles of CMS-SS-MP@mPEG with their counterparts without the grafting of hydrophilic PEG, it was found that mPEG chains did not hinder the drug release due to the cleavable disulfide bonds and the improved dispersibility. Overall, this work provides a new strategy to connect thiol-containing/thiolated drugs and hydrophilic polymers to the interior and exterior of silica via disulfide bonds to obtain redox-responsive release and improve the dispersibility and biocompatibility of silica. (C) 2014 Elsevier B.V. All rights reserved.
Oligomer-Nucleoside Phosphate Conjugates
申请人:Ren Zhongxu
公开号:US20100286084A1
公开(公告)日:2010-11-11
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES
申请人:NEKTAR THERAPEUTICS
公开号:US20140371168A1
公开(公告)日:2014-12-18
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages over previously administered compounds.